

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Trajectory research in children on the autism spectrum: A scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053443
Article Type:	Protocol
Date Submitted by the Author:	13-May-2021
Complete List of Authors:	Gentles, Stephen; McMaster University, Department of Psychiatry and Behavioural Neurosciences Duku, Eric; McMaster University, Department of Psychiatry and Behavioural Neurosciences Kerns, Connor ; The University of British Columbia, Department of Psychology McVey, Alana; The University of British Columbia, Department of Psychology Hunsche, Michelle; The University of British Columbia, Department of Psychology Ng-Cordell, Elise; The University of British Columbia, Department of Psychology Bednar, E.; McMaster University, Michael G. DeGroot School of Medicine Banfield, Laura; McMaster University, Health Sciences Library Szatmari, Peter; University of Toronto, Department of Psychiatry; Centre for Addiction and Mental Health Georgiades, Stelios; McMaster University, Department of Psychiatry and Behavioural Neurosciences
Keywords:	Child & adolescent psychiatry < PSYCHIATRY, PAEDIATRICS, Developmental neurology & neurodisability < PAEDIATRICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Trajectory research in children on the autism spectrum: A scoping review protocol

Gentles, Stephen J., Offord Centre For Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, [stevegentles@gmail.com](mailto:stevegentles@gmail.com)

Duku, Eric, Offord Centre For Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, [duku@mcmaster.ca](mailto:duku@mcmaster.ca)

Kerns, Connor M., Department of Psychology, University of British Columbia, [cmkerns@psych.ubc.ca](mailto:cmkerns@psych.ubc.ca)

McVey, Alana J., Department of Psychology, University of British Columbia, [amcvey@psych.ubc.ca](mailto:amcvey@psych.ubc.ca)

Hunsche, Michelle C., Department of Psychology, University of British Columbia, [michelle.hunsche@psych.ubc.ca](mailto:michelle.hunsche@psych.ubc.ca)

Ng-Cordell, Elise C., Department of Psychology, University of British Columbia, [elise.ngcordell@psych.ubc.ca](mailto:elise.ngcordell@psych.ubc.ca)

Bednar, E. Dimitra, Michael G. DeGroot School of Medicine, McMaster University, [dimitra.bednar@medportal.ca](mailto:dimitra.bednar@medportal.ca)

Laura Banfield, Health Sciences Library, McMaster University, [banfie@mcmaster.ca](mailto:banfie@mcmaster.ca)

Szatmari, Peter, Department of Psychiatry, Hospital for Sick Children, University of Toronto, Centre for Addiction and Mental Health, Toronto. [Peter.szatmari@utoronto.ca](mailto:Peter.szatmari@utoronto.ca)

1  
2  
3 Geogiades, Stelios, Offord Centre For Child Studies, Department of Psychiatry and  
4  
5 Behavioural Neurosciences, McMaster University, [georgis@mcmaster.ca](mailto:georgis@mcmaster.ca)  
6  
7  
8  
9

10  
11 Corresponding author:  
12

13  
14 Gentles, Stephen J., Offord Centre For Child Studies, McMaster University, Department of  
15  
16 Psychiatry and Behavioural Neurosciences, 175 Longwood Road South, Hamilton, Ontario, L8P  
17  
18 0A1, Canada, [stevegentles@gmail.com](mailto:stevegentles@gmail.com)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction.** Longitudinal trajectory methods, featuring outcome assessments at three or more timepoints, are increasingly being used as appropriate approaches to understand developmental pathways of people on the autism spectrum across the lifespan. Understanding the scope of this rapidly expanding body of research can help inform future trajectory studies and identify areas for potential meta-analysis as well as key evidence gaps. The objective of this scoping review is to identify and summarize the scope of research that uses a longitudinal trajectory study design to examine development in children diagnosed with autism. Specifically, we will identify outcome domains and age intervals that have been well-characterized, areas where further research is needed, and the historical use of various longitudinal trajectory analytic approaches.

**Methods and analysis.** We outline the methods for the proposed scoping review according to the framework outlined by Arksey and O'Malley, with subsequent clarifications and enhancements by other authors. Using a search strategy developed by a medical librarian, we will search six databases for relevant publications. Titles and abstracts will be screened in duplicate, followed by full-text screening. Data extraction fields developed predominantly *a priori* from a set of guiding sub-questions will be used to chart relevant data. The findings will include quantitative aggregate summaries, narrative summaries, and appraisal of trajectory studies according to our methodological sub-questions. We will consult Autistic self-advocate and parent-caregiver stakeholders to facilitate interpretation of the findings.

**Ethics and dissemination.** Research ethics approval is not required for this scoping review. The results will be presented to researcher, care professional, policy-maker, and

1  
2  
3 stakeholder audiences at local and international conferences, other dissemination activities, and  
4  
5 published in a peer-reviewed journal.  
6  
7  
8  
9

## 10 11 **Keywords**

12  
13  
14 Autism, longitudinal research, trajectory studies, scoping review, child development  
15

## 16 17 **Word count**

18  
19 3636 words  
20  
21  
22  
23  
24

## 25 26 **Article Summary**

27  
28 ‘Strengths and limitations of this study’  
29

- 30  
31 • This scoping review of will be the first to establish which outcome domains and age intervals  
32  
33 have been characterized by longitudinal trajectory research examining development in  
34  
35 children diagnosed with autism, and which warrant further study.  
36  
37
- 38  
39 • An innovative aspect of this scoping review is its use of pre-specified sub-questions to guide  
40  
41 development of the extraction (charting) form.  
42
- 43  
44 • We will summarize information corresponding to methodological sub-questions that may  
45  
46 provide a useful basis for future critical appraisal of trajectory studies in this area.  
47
- 48  
49 • This review is limited in its scope because it excludes trajectory studies whose focus is on  
50  
51 adulthood, and a separate review is therefore warranted to report on trajectories of outcome  
52  
53 domains that may only be relevant at later life stages.  
54  
55  
56  
57

## Background

Autism (autism spectrum disorder) is a neurodevelopmental condition recently estimated to affect 1 in 54 children [1], the prevalence of which is not likely to be substantively affected by geography, race, or socioeconomic factors [2]. The diagnosis is defined by variation in social communication and interaction, and restricted, repetitive patterns of behaviour, interests, or activities [3]. Autism is also increasingly being understood to be characterized by different strengths [4]. It has long been recognized that the characteristics used to define autism vary developmentally over the life-course, and that there is a need for rigorous longitudinal research to understand changes in relevant outcomes over time, identify prognostic factors, and understand what may improve developmental pathways of relevant outcome domains [5].

Trajectory methodology, defined here as featuring longitudinal analysis of assessments at three or more time points, has emerged as more appropriate for understanding development in autism compared to traditional cohort studies characterized by assessments at only two timepoints. In an early review of longitudinal research in autism that included studies with traditional cohort and cross-sectional designs, Selzer and colleagues [6] highlighted the key limitations of research featuring assessments at only two timepoints, noting it “makes it impossible to characterize the shape of the developmental function, the timing of changes, or the possibility that there are different subtypes of individuals on the autism spectrum characterized by different trajectories to the same outcome.” Recognizing these limitations, researchers in the field of autism have increasingly turned to trajectory methods, which feature assessments at three or more time points. Some large-scale longitudinal autism cohort research groups have published serial reports on the development of their child cohorts, increasing the number of assessments as they age over time (for example, [7, 8]). Such research has expanded our understanding of



1  
2  
3 autism in important ways, including by defining important variation in the developmental  
4 trajectories of children on the autism spectrum—variation that exists both between trajectory  
5 groups or clusters, and between children within those clusters (for example see, [9-11]).  
6  
7

8  
9  
10 Consequently, other approaches, which simply report or graph average measures across  
11 individuals at each timepoint, have limited use for studying development in people on the autism  
12 spectrum, because they ignore and obscure the correlated nature of within-case data over time.  
13  
14  
15

16  
17 Given the expansion of published trajectory studies in autism, there is a need to understand  
18 its scope to provide a broad picture of aspects such as the variety of outcome domains (i.e.,  
19 measurable outcomes, which potentially vary over development) that have been studied over  
20 time, the age intervals over which outcome domains have been followed, and trends in the  
21 statistical analytic approaches that have been used. Two broad types of analytic approaches have  
22 been used to study autism trajectories: multi-level modeling (MLM), a variable-centred approach  
23 that estimates the average intercept and slope of the outcome domain of interest for pre-defined  
24 cohort groups (e.g., autistic, non-autistic); and growth mixture modeling (GMM), a person-  
25 centred approach that estimates distinct trajectories of latent groups formed on the basis of  
26 similar trajectories of individual participants within a cohort population.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 ***Previous reviews.*** The early reviews on longitudinal studies in autism (published 2004–  
42 2013) of which we are aware neglected to report a systematic search strategy, and have at least  
43 some focus on adults on the autism spectrum [5, 6, 12]. Three subsequent reviews of longitudinal  
44 autism research (published 2014 onwards), which did report a systematic search strategy,  
45 included studies following up to adulthood. Magiati and colleagues [13] included 25 studies and  
46 summarized findings from multiple outcome domains including cognitive ability, language,  
47 adaptive functioning, autism severity, and social functioning; a focus of this review was  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 childhood predictors of later outcomes, and a mix of studies using trajectory and traditional two-  
4  
5 timepoint cohort designs were included but not separated from each other in the review.  
6

7 Bieleninik and colleagues [14] conducted a systematic review and meta-analysis that included 35  
8  
9 prospective cohort studies and 5 randomized controlled trials, and evaluated two outcome  
10  
11 domains: diagnostic stability, and autism symptom severity; trajectory studies were not  
12  
13 distinguished from two-timepoint follow-up studies. Howlin and Magiati [15] reviewed all adult  
14  
15 outcome-focused research (43 studies), of which five were trajectory studies described  
16  
17 individually in a separate section. A search for existing published (PubMed) or registered  
18  
19 (PROSPERO) protocols did not reveal other scoping reviews of trajectory studies in autism  
20  
21  
22  
23  
24 research.  
25

26  
27 Our planned scoping study will be the first we are aware of to review research that uses a  
28  
29 longitudinal trajectory study design to study change in outcome domains over time in children on  
30  
31 the autism spectrum (to age 18). Notably, it will exclude studies whose focus is on adulthood  
32  
33 (i.e., where at least half of age timepoints assessed are above 18 years), because the set of  
34  
35 outcome domains that are relevant after the transition to adulthood differs sufficiently from  
36  
37 childhood, in our view, to warrant a separate review. Namely, some domains relevant to early  
38  
39 development (e.g., language) are generally less relevant in adulthood, while numerous adult-  
40  
41 relevant domains are inapplicable to early childhood (e.g., employment status, romantic  
42  
43 relationships). The planned review will address the breadth of outcome domains relevant to  
44  
45 children on the autism spectrum including clinical (developmental, behavioral, functional),  
46  
47 educational (e.g., academic achievement), and social. We will, however, exclude studies of  
48  
49 trajectories of neuroanatomical or physiological development, which have been previously  
50  
51 reviewed [16, 17].  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Objectives**

The primary objective of this scoping review is to identify and summarize the scope of research that uses a longitudinal trajectory study design (with three or more timepoints) to study the progression of different outcome domains—including the shape, timing and sub-groups—in children on the autism spectrum (to age 18). A secondary objective is to summarize methodological trends in terms of analytic approaches used in trajectory studies of child development in autism research. Findings from this review will provide a useful understanding of 1) how and where trajectory research has already been used, and the areas where future trajectory research can produce needed knowledge about autism (gaps), 2) specific outcome domains or research questions for which sufficient data exist to conduct more focused quantitative systematic reviews or meta-analyses, and 3) the general utility and value of trajectory study methodology for providing actionable knowledge to support positive development of children on the autism spectrum.

## **Methods and Analysis**

The scoping review methodology was judged to be appropriate for this review topic given its breadth, objectives, and the lack of known recent reviews on similar topics [18]. We outline the methods here according to the scoping review framework put forth by Arksey and O'Malley [19], informed by subsequent clarifications and enhancements [20, 21], reporting relevant elements outlined in the corresponding PRISMA Extension for Scoping Reviews (PRISMA-ScR) [22].

### *Stage 1: identifying the research question*

The primary objective and corresponding research question for this review was informed by the experience of review group members with trajectory studies of children on the autism spectrum (e.g., [7, 23, 24]) and by an examination of existing reviews on the topic which identified three narrative reviews in children [6, 16, 17] and five additional reviews of trajectories to adulthood [5, 12-15]. In addition to helping confirm the appropriateness and need for our focus on children, the examination of existing reviews helped us understand the potential scope of the literature and, later, to iteratively exclude two research categories we felt represented distinct topics of interest warranting separate reviews: 1) studies of trajectories of neuroanatomical or physiological development, and 2) descriptive case studies or case series of individual trajectories. The two primary research questions for this review that we used to inform study identification and selection are as follows:

- How has research that employs a longitudinal trajectory study design (i.e., featuring three or more timepoints and an aggregative statistical analysis that accounts for the correlated nature of within-case data over time) been used to produce knowledge about the change—including shape, timing and sub-groups—in child developmental, behavioral, functional, social, or outcome domains in children on the autism spectrum (to age 18)?
- What are some of the key methodological characteristics of this research?

The first question above identifies the key domains of our search strategy and screening criteria, namely the population (diagnosis and age), methodology, and outcome domains measured (i.e., non-anatomical). Under the umbrella of the primary research questions, lead

investigators on this review (SG, ED, SJG) also developed a set of sub-questions (Table 1) that were used to plan the data extraction and reporting of results, described below.

Table 1. Sub-questions to guide data extraction

<i>Questions about scope of the research</i>
1. What outcome domains have been studied in trajectory studies?
2. What outcome measures have been used to follow the different outcome domains over time?
3. What ages have been characterized for each outcome domain?
4. For studies using person-centred (GMM) approaches, how many trajectory groups (or clusters) have been defined for different outcome domains followed in different trajectory studies?
5. What and where are the different autism cohort research groups that have reported trajectory study findings?
6. To what extent have each of the different autism cohort research groups contributed to the trajectory study literature, and what are the general characteristics of their research (narrative summary)?
7. To what extent have the proposed implications (utility) of trajectory study findings been reported clearly?
8. How much impact (in terms of citation metrics) have different sources or types of trajectory research had?

***Questions about methodological aspects of research***

1. What terms (text words) have been used to describe multi-level modeling (MLM) and growth mixture modeling (GMM) trajectory studies of child development in autism?
2. How has the historical prevalence of MLM- and GMM-type trajectory approaches for studying development of children on the autism spectrum evolved by year?
3. How do select study characteristics (e.g., sample size, comparison to non-autism groups) vary between MLM- and GMM-type studies?
4. How reliable is the ascertainment of autism diagnosis in trajectory studies?
5. To what extent was representative sampling used across trajectory studies?
6. What other methodological aspects of trajectory research in autism could be used as a basis for identifying sources of risk of bias or for quality reporting standards?

***Stage 2: identifying relevant studies***

Our search was informed by the domains of the primary research question described above, and developed with the help of a medical librarian (LB), starting with Medline (OVID) because the subject heading definitions of this database are well developed (Table 2).

Table 2. MEDLINE search strategy.

1	exp Autism Spectrum Disorder/
2	Child Development Disorders, Pervasive/

3	Asperger*.mp.
4	ASD.mp.
5	autis*.mp.
6	or/1-5
7	exp Child/
8	child*.mp.
9	Adolescent/
10	Infant/
11	Infant, Newborn/
12	infan*.mp.
13	newborn*.mp.
14	Child, Preschool/
15	Child Development/
16	adolescen*.mp.
17	Pediatrics/
18	youth.mp.
19	teen*.mp.
20	p?ediatric*.mp.

21	or/7-20
22	trajector*.mp.
23	Longitudinal Studies/
24	Follow-Up Studies/
25	Prospective Studies/
26	longitudinal*.mp.
27	follow-up stud*.mp.
28	prospective*.mp.
29	followup stud*.mp.
30	Cohort Studies/
31	(cohort* stud* or cohort analys?s).mp.
32	panel stud*.mp.
33	or/22-32
34	6 and 21 and 33

The MEDLINE search was translated into the five other databases to be searched: EMBASE, CINAHL, PSYCInfo, ERIC, Cochrane Database of Systematic Reviews. Search results will be imported into EndNote reference management software (Clarivate Analytics), where duplicates will be removed and citations managed in the subsequent screening stages. We will not search the grey literature or conference proceedings, because we are interested in



1  
2  
3 mapping successfully peer-reviewed published literature that is likely to influence the field. For  
4  
5 similar reasons, we will exclude doctoral theses or dissertations retrieved by the searches.  
6

7  
8 Searches will not be restricted by language or year of publication.  
9

### 10 11 ***Stage 3: study selection*** 12

13  
14 After removal of duplicates from our EndNote database, we will select articles for  
15  
16 inclusion in the review through a two-step screening process: title and abstract, and full-text  
17  
18 screening. In both steps, all records will be screened in duplicate (by two reviewers), and  
19  
20 disagreements will be resolved through consensus in regular meetings. Reviewer decisions will  
21  
22 be recorded in EndNote, with mutual consensus required before an include or exclude decision is  
23  
24 reached. For the first step, title and abstract screening, screening decisions will err on the side of  
25  
26 inclusivity (sensitivity), so that records for which insufficient information is available in the title  
27  
28 or abstract will be included, and passed on, to the second screening step. Based on preliminary  
29  
30 work, in this step we expect to partially filter records based on indicators of diagnosis (autism),  
31  
32 age, and methodology (trajectory design), and definitively exclude records based on their identity  
33  
34 as case studies or series, trajectories of neuroanatomy or physiology, or non-published status  
35  
36 (e.g., dissertations or theses).  
37  
38  
39  
40  
41

42 In the second step, the full text of articles will be retrieved (in PDF) and read to confirm  
43  
44 eligibility. Based on preliminary work, one of the predominant decisions in this step will be to  
45  
46 determine if studies qualify as true trajectory study methodology both in terms of the data  
47  
48 collection criterion (three timepoints or more) and two analysis criteria (analysis accounts for the  
49  
50 correlated nature of within-case data over time; and analysis does not simply average measures  
51  
52 across individuals at each timepoint yielding only cross-sectional estimates). Given the potential  
53  
54 number and complexity of analytic techniques, a statistician will be involved as a second  
55  
56  
57  
58  
59  
60

reviewer for full-text screening decisions involving analysis-related criteria where necessary.

Reasons for exclusions at the full-text screening step will be recorded in EndNote. A PRISMA flow-chart will be used to report the results of the searches and both screening steps.

#### ***Stage 4: charting the data***

The fields that we will extract data on (Table 3) have been developed as much as possible, a priori, from the sub-questions listed in Table 1. These fields are captured in an initial extraction form designed in Word, with the input of lead investigators (SG, ED, SJG) and the extraction team, to streamline the extraction process (e.g., containing in-line instructions, and other needed reference information). This form was piloted by the four-person extraction team (SJG, MCH, AJM, ENA) who each independently applied it to one paper for training and reliability purposes. The form was judged easy to use by all, there was little disagreement, and misunderstandings were discussed and corrected. We anticipate it will be possible to develop a relatively stable form for addressing the pre-specified sub-questions. Nevertheless, we expect some unanticipated but important extraction fields will become apparent in the course of reviewing the included literature, which may require the iterative adaptation of the extraction form. Consequently, we have included a field in the extraction form to record ideas or suggestions for adaptation or revision that may iteratively arise when reviewing a specific article.

Information regarding methodological quality of individual studies will be extracted to address two of our sub-questions. Some extraction fields pertaining to trajectory methodology will be developed iteratively as there are no existing methodological quality criteria that we are aware of for this study design, and it is not possible to anticipate all aspects of quality in advance of reviewing this literature. Additionally, quality indicators already accepted in the field of

epidemiological autism research will be extracted, namely those pertaining to research-level diagnostic ascertainment standards.

Given the inevitability that there will be multiple publications by the same study group on the same cohort as it is reported on over multiple age timepoints, it may be possible to find helpful information pertaining to a given study in other publications by the same cohort research group. In addition to keeping careful records of which publications are linked in this way (as an extraction and reporting field of interest), we will assign papers belonging to the same cohort group to the same extractor so they can be aware of, and cross-reference as needed, the shared context of linked papers while extracting.

While articles will be extracted individually, we will have regular extraction meetings to discuss challenging articles, ideas for revising the extraction form, and other issues. Additionally, extractors will be able to consult with each other regarding areas of uncertainty related to specific publications. Finally, completed extraction forms will be verified by the review coordinator (SJG) before transferring their data to the analysis database, maintained in Excel, which will allow for aggregative summary and cross-tabulation of the extracted data. Fields in the Excel form will be programmed with data validation settings to minimize errors in data entry.

Table 3. Information fields for extraction from each included publication

Category	Information extraction field
Article characteristics	<ul style="list-style-type: none"> <li>• Year of publication</li> <li>• Article impact</li> <li>• Country(ies) of origin of cohort</li> </ul>

	<ul style="list-style-type: none"> <li>• Purpose of trajectory study (narrative)</li> <li>• Applicability of findings (narrative)</li> <li>• Clarity of applicability of findings</li> </ul>
Cohort research group	<ul style="list-style-type: none"> <li>• Autism Cohort Research Group: Title</li> <li>• Autism Cohort Research Group: Lead author</li> </ul>
Sample	<ul style="list-style-type: none"> <li>• Sample setting (community-based, clinical, etc.)</li> <li>• Type of sampling of autism participants (non-representative, representative)</li> <li>• Sample size, overall</li> <li>• Sample size, autism only</li> </ul>
Diagnostic ascertainment	<ul style="list-style-type: none"> <li>• Autism diagnosis methods reported?</li> <li>• Use of Autism Diagnostic Observation Schedule</li> <li>• Use of Autism Diagnostic Interview-Revised</li> <li>• Clinical judgment used</li> </ul>
Analysis	<ul style="list-style-type: none"> <li>• Prospective</li> <li>• MLM-type</li> <li>• MLM terms used</li> <li>• GMM-type</li> <li>• GMM terms used</li> </ul>

	<ul style="list-style-type: none"> <li>• Clarity of ages of assessment</li> </ul>
<p>Outcome domain (repeated for each domain)</p>	<ul style="list-style-type: none"> <li>• Outcome domain name</li> <li>• Measure used</li> <li>• Age interval start</li> <li>• Age interval end</li> <li>• Number of timepoints assessed</li> <li>• Ages of timepoints assessed</li> <li>• Rationale for ages assessed (narrative)</li> <li>• Clinical schedule used</li> <li>• Number of trajectory groups (clusters) defined</li> </ul>

### ***Stage 5: collating, summarising and reporting the results***

Along with presenting standard publication retrieval in a PRISMA flow chart, we plan to report on the number of unique studies that were captured by each successive database, from MEDLINE, to Embase, PsycINFO, CINAHL, ERIC, and Cochrane Reviews.

We expect a high number of included studies (>60), which may affect the level of aggregation we employ to summarize data presentations. We plan to present a summary table displaying key characteristics of the extracted literature, organized hierarchically by country, major cohort research group (where applicable), and individual publication (as hierarchically indented rows); and include citations for each of the characteristics presented in columns—

1  
2  
3 including sample sizes, outcome domains followed, age interval followed, number of time  
4  
5 points, analytic approach, and citation impact. We also plan to use graphs to visually represent  
6  
7 data on historical trends in the use of MLM versus GMM analytic approaches over time, and on  
8  
9 the density of age timepoint assessments for each outcome domain. In addition, we will present  
10  
11 data that may provide a useful basis for future critical appraisal of trajectory studies according to  
12  
13 our methodological sub-questions regarding autism diagnosis ascertainment, and trajectory  
14  
15 review method reporting criteria. A table will display a proposed set of text words that can be  
16  
17 used to search for each type of trajectory analysis approach (MLM and GMM) in future.  
18  
19

20  
21  
22 A section of the review will provide narrative summaries to address the sub-question  
23  
24 regarding the impact and extent to which the major autism cohort research groups have  
25  
26 contributed to the trajectory study literature including general characteristics of their research.  
27  
28 Narrative will also be used to provide interpretive commentary on other sub-question-related  
29  
30 aspects, including suitability of the outcome measures that have been used to follow the different  
31  
32 outcome domains over time (including their patient-centeredness, per stakeholder consultation  
33  
34 described below), the number of trajectory groups (clusters) that have been defined for different  
35  
36 outcome domains, the extent to which the implications (or utility) of trajectory study findings  
37  
38 have been reported clearly, and the merit of future research to target gaps in the ages or outcome  
39  
40 domains not previously assessed.  
41  
42  
43  
44  
45

### 46 ***Patient and Public Involvement***

47  
48  
49 Corresponding to Stage 6 of the Arksey–O'Malley scoping review framework (*optional*  
50  
51 *consultation exercise*), we have engaged two stakeholders in this review—an adult Autistic self-  
52  
53 advocate and a parent of a child on the autism spectrum—to provide feedback at key points. For  
54  
55 purposes of this protocol, they have provided early feedback on aspects of the planned extraction  
56  
57  
58  
59  
60

1  
2  
3 related to outcome domains. This feedback informed plans for interpreting the relevance and  
4 importance of different outcomes in the final report, but it did not alter our decision to extract  
5 and report on all outcomes assessed by the studies to be included in this review. We did not  
6 involve patient stakeholders in development of the research question, or design of this study.  
7  
8 While they will not be involved in data collection or analysis, we will re-engage these  
9 individuals once the review is complete to provide interpretations of the findings from their  
10 perspectives as members of the stakeholder community. Their interpretations will be used to  
11 inform the discussion of findings. We will also involve these individuals in presentations of the  
12 results described in the next section, according to their interest.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **Ethics and Dissemination**

25  
26  
27 The research ethics boards at our institutions do not need to be engaged to provide ethics  
28 approval for consulting with stakeholders about this research project since it does not involve  
29 their providing study data. We will follow best practices for patient engagement in research.  
30  
31  
32  
33

34  
35 This review will represent a source of valuable knowledge and guidance to researchers  
36 who are currently engaged in, or planning to conduct, longitudinal research on child  
37 development in autistic samples. It will also be of interest to clinicians, policy makers, and other  
38 professionals responsible for care or services for children on the autism spectrum, allowing them  
39 to quickly identify the trajectory literature on clinically-relevant outcome domains. It will also be  
40 of interest to families of children on the autism spectrum, who are known for their desire for  
41 access to research findings, by providing an overview of the kind of research that is often  
42 conducted to find answers about “what to expect” during the development of children on the  
43 autism spectrum. Finally, it will be useful to other reviewers seeking to identify one or more  
44 outcome domains for which there is sufficient published trajectory research data to conduct a  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 systematic review or meta-analysis. To reach these audiences, we plan to disseminate findings at  
4 major international autism research conferences, local autism conferences attended by families,  
5 and to publish the completed review in open access format in a peer-reviewed autism research  
6 journal. Other dissemination activities include plans to develop a webinar for parent and  
7 professional audiences, and lay research summaries for publication on provincial and national  
8 autism organization web sites.  
9

### 16 **Acknowledgments**

17  
18  
19  
20 The authors would also like to thank Trudy Goold and Connie Putterman for providing  
21 feedback from a stakeholder perspective on aspects of the proposed data extraction.  
22  
23

### 24 **Author contributions**

25  
26  
27  
28 SJG, SG, and ED led the design and conceptualization. EDB, LB, and SJG developed the  
29 search strategy. AJM, EN-C, MCH, CMK, and PS were involved in design and conceptualization  
30 of the extraction form. SJG drafted the protocol. SG, ED, AJM, EN-C, MCH, CMK, and PS  
31 provided feedback and helped revise drafts of this manuscript for important intellectual content  
32 and clarity.  
33  
34  
35  
36  
37  
38  
39

### 40 **Funding**

41  
42  
43 This research received no specific grant from any funding agency in the public,  
44 commercial or not-for-profit sectors.  
45  
46  
47  
48  
49

### 50 **Competing interests**

51  
52  
53  
54 None declared.  
55  
56  
57



## References

1. Maenner, M.J., K.A. Shaw, J. Baio, EdS1, A. Washington, *et al.* Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. *MMWR Surveillance summaries : Morbidity and mortality weekly report Surveillance summaries / CDC*, 2020; 69(4): 1-12.  
<https://doi.org/10.15585/mmwr.ss6904a1>
2. Elsabbagh, M., G. Divan, Y.-J. Koh, Y.S. Kim, S. Kauchali, *et al.* Global prevalence of autism and other pervasive developmental disorders. *Autism Research*, 2012; 5(3): 160-179.  
<https://doi.org/10.1002/aur.239>
3. Association, A.P. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013: American Psychiatric Association. 1-36.
4. Mahdi, S. An International Clinical Study of Ability and Disability in Autism Spectrum Disorder Using the WHO-ICF Framework. *Journal of Autism and Developmental Disorders*, 2018; 48(6): 2148-2163. <https://doi.org/10.1007/s10803-018-3482-4>
5. Howlin, P. and P. Moss. Adults with autism spectrum disorders. *Canadian journal of psychiatry Revue canadienne de psychiatrie*, 2012; 57(5): 275-283.  
<https://doi.org/10.1177/070674371205700502>
6. Seltzer, M.M., P. Shattuck, L. Abbeduto, and J.S. Greenberg. Trajectory of development in adolescents and adults with autism. *Ment Retard Dev Disabil Res Rev*, 2004; 10(4): 234-47.  
<https://doi.org/10.1002/mrdd.20038>

- 1  
2  
3 7. Szatmari, P., S. Georgiades, E. Duku, T.A. Bennett, S. Bryson, *et al.* Developmental  
4 trajectories of symptom severity and adaptive functioning in an inception cohort of preschool  
5 children with autism spectrum disorder. *JAMA Psychiatry*, 2015; 72(3): 276-83.  
6  
7  
8  
9  
10 <https://doi.org/https://dx.doi.org/10.1001/jamapsychiatry.2014.2463>  
11  
12  
13 8. Gotham, K., A. Pickles, and C. Lord. Trajectories of autism severity in children using  
14 standardized ADOS scores. *Pediatrics*, 2012; 130(5): e1278-e1284.  
15  
16  
17 <https://doi.org/http://dx.doi.org/10.1542/peds.2011-3668>  
18  
19  
20 9. Georgiades, S., S.L. Bishop, and T. Frazier. Editorial Perspective: Longitudinal research  
21 in autism - introducing the concept of 'chronogeneity'. *Journal of Child Psychology and*  
22  
23  
24  
25 *Psychiatry*, 2017; 58(5): 634-636. <https://doi.org/10.1111/jcpp.12690>  
26  
27  
28 10. Charman, T. Mapping Early Symptom Trajectories in Autism Spectrum Disorder:  
29 Lessons and Challenges for Clinical Practice and Science. *Journal of the American Academy of*  
30  
31  
32  
33  
34 *Child and Adolescent Psychiatry*, 2018; 57(11): 820-821.  
35  
36 <https://doi.org/10.1016/j.jaac.2018.06.021>  
37  
38 11. Kim, S.H., V.H. Bal, N. Benrey, Y.B. Choi, W. Guthrie, *et al.* Variability in Autism  
39 Symptom Trajectories Using Repeated Observations From 14 to 36 Months of Age. *J Am Acad*  
40  
41  
42  
43  
44 *Child Adolesc Psychiatry*, 2018; 57(11): 837-848 e2. <https://doi.org/10.1016/j.jaac.2018.05.026>  
45  
46 12. Henninger, N.A. and J.L. Taylor. Outcomes in adults with autism spectrum disorders: a  
47 historical perspective. *Autism*, 2013; 17(1): 103-116. <https://doi.org/10.1177/1362361312441266>  
48  
49  
50 13. Magiati, I., X.W. Tay, and P. Howlin. Cognitive, language, social and behavioural  
51 outcomes in adults with autism spectrum disorders: A systematic review of longitudinal follow-  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 14. Bieleninik, L., M.B. Posserud, M. Geretsegger, G. Thompson, C. Elefant, and C. Gold.  
4 Tracing the temporal stability of autism spectrum diagnosis and severity as measured by the  
5 Autism Diagnostic Observation Schedule: A systematic review and meta-analysis. *PLoS One*,  
6 2017; 12(9): e0183160. <https://doi.org/10.1371/journal.pone.0183160>  
7  
8  
9  
10  
11  
12  
13 15. Howlin, P. and I. Magiati. Autism spectrum disorder: outcomes in adulthood. *Current*  
14 *Opinion in Psychiatry*, 2017; 30(2): 69-76. <https://doi.org/10.1097/YCO.0000000000000308>  
15  
16  
17  
18 16. Baribeau, D.A. and E. Anagnostou. A comparison of neuroimaging findings in childhood  
19 onset schizophrenia and autism spectrum disorder: a review of the literature. *Front Psychiatry*,  
20 2013; 4: 175. <https://doi.org/10.3389/fpsyt.2013.00175>  
21  
22  
23  
24  
25 17. Lainhart, J.E. Brain imaging research in autism spectrum disorders: in search of  
26 neuropathology and health across the lifespan. *Curr Opin Psychiatry*, 2015; 28(2): 76-82.  
27  
28 <https://doi.org/10.1097/yco.0000000000000130>  
29  
30  
31  
32  
33 18. Pollock, D., E.L. Davies, M.D.J. Peters, A.C. Tricco, L. Alexander, *et al.* Undertaking a  
34 scoping review: A practical guide for nursing and midwifery students, clinicians, researchers,  
35 and academics. *Journal of Advanced Nursing*, 2021; 77(4): 2102-2113.  
36  
37 <https://doi.org/10.1111/jan.14743>  
38  
39  
40  
41  
42 19. Arksey, H. and L. O'Malley. Scoping studies: towards a methodological framework.  
43 *International Journal of Social Research Methodology*, 2005; 8(1): 19-32.  
44  
45  
46  
47 20. Levac, D., H. Colquhoun, and K.K. O'Brien. Scoping studies: advancing the  
48 methodology. *Implementation science : IS*, 2010; 5(1): 69. [https://doi.org/10.1186/1748-5908-5-](https://doi.org/10.1186/1748-5908-5-69)  
49  
50  
51  
52 [69](https://doi.org/10.1186/1748-5908-5-69)  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 21. O'Brien, K.K., H. Colquhoun, D. Levac, L. Baxter, A.C. Tricco, *et al.* Advancing  
4 scoping study methodology: a web-based survey and consultation of perceptions on terminology,  
5 definition and methodological steps. 2016; 16(1): 1-12. [https://doi.org/10.1186/s12913-016-](https://doi.org/10.1186/s12913-016-1579-z)  
6  
7  
8  
9  
10 [1579-z](https://doi.org/10.1186/s12913-016-1579-z)  
11  
12  
13 22. Tricco, A.C., E. Lillie, W. Zarin, K.K. O'Brien, H. Colquhoun, *et al.* PRISMA  
14  
15 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Annals of Internal*  
16  
17 *Medicine*, 2018; 169(7): 467-19. <https://doi.org/10.7326/M18-0850>  
18  
19  
20 23. Szatmari, P., S. Bryson, E. Duku, L. Vaccarella, L. Zwaigenbaum, *et al.* Similar  
21  
22 developmental trajectories in autism and Asperger syndrome: from early childhood to  
23  
24 adolescence. *Journal of Child Psychology & Psychiatry & Allied Disciplines*, 2009; 50(12):  
25  
26 1459-67. <https://doi.org/https://dx.doi.org/10.1111/j.1469-7610.2009.02123.x>  
27  
28  
29  
30 24. Di Rezze, B., E. Duku, P. Szatmari, J. Volden, S. Georgiades, *et al.* Examining  
31  
32 Trajectories of Daily Living Skills over the Preschool Years for Children with Autism Spectrum  
33  
34 Disorder. *Journal of Autism and Developmental Disorders*, 2019: 1-10.  
35  
36 <https://doi.org/10.1007/s10803-019-04150-6>  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
<b>Title</b>			
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	na
<b>Registration</b>			
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	na
<b>Authors</b>			
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	2
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the	21

guarantor of the review

## Amendments

[#4](#) If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

na

## Support

Sources [#5a](#) Indicate sources of financial or other support for the review 21

Sponsor [#5b](#) Provide name for the review funder and / or sponsor Na

Role of sponsor or funder [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol Na

## Introduction

Rationale [#6](#) Describe the rationale for the review in the context of what is already known 5-7

Objectives [#7](#) Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) 8-9

## Methods

Eligibility criteria [#8](#) Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 11-14

Information sources [#9](#) Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 13

Search strategy [#10](#) Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 11-13

Study records - data management [#11a](#) Describe the mechanism(s) that will be used to manage records and data throughout the review 13-14

Study records - [#11b](#) State the process that will be used for selecting studies (such as 14-15

1	selection process		two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	
2				
3				
4	Study records -	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as	15-16
5	data collection		piloting forms, done independently, in duplicate), any processes	
6	process		for obtaining and confirming data from investigators	
7				
8				
9	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as	16-17
10			PICO items, funding sources), any pre-planned data assumptions	
11			and simplifications	
12				
13				
14	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought,	16-17
15	prioritization		including prioritization of main and additional outcomes, with	
16			rationale	
17				
18				
19				
20	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of	15-16
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will be	
23			used in data synthesis	
24				
25				
26				
27	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be quantitatively	18-19
28			synthesised	
29				
30	Data synthesis	<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe planned	18-19
31			summary measures, methods of handling data and methods of	
32			combining data from studies, including any planned exploration	
33			of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	
34				
35				
36				
37	Data synthesis	<a href="#">#15c</a>	Describe any proposed additional analyses (such as sensitivity or	Na
38			subgroup analyses, meta-regression)	
39				
40				
41	Data synthesis	<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the type of	18-19
42			summary planned	
43				
44				
45	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such as	Na
46			publication bias across studies, selective reporting within studies)	
47				
48				
49	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be	na
50	cumulative		assessed (such as GRADE)	
51	evidence			
52				
53				

None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Trajectory research in children on the autism spectrum: A scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053443.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Oct-2021
Complete List of Authors:	Gentles, Stephen; McMaster University, Department of Psychiatry and Behavioural Neurosciences Duku, Eric; McMaster University, Department of Psychiatry and Behavioural Neurosciences Kerns, Connor ; The University of British Columbia, Department of Psychology McVey, Alana; The University of British Columbia, Department of Psychology Hunsche, Michelle; The University of British Columbia, Department of Psychology Ng-Cordell, Elise; The University of British Columbia, Department of Psychology Bednar, E.; McMaster University, Michael G. DeGroote School of Medicine Banfield, Laura; McMaster University, Health Sciences Library Szatmari, Peter; University of Toronto, Department of Psychiatry; Centre for Addiction and Mental Health Georgiades, Stelios; McMaster University, Department of Psychiatry and Behavioural Neurosciences
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Epidemiology
Keywords:	Child & adolescent psychiatry < PSYCHIATRY, PAEDIATRICS, Developmental neurology & neurodisability < PAEDIATRICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Trajectory research in children on the autism spectrum: A scoping review protocol

Gentles, Stephen J., Offord Centre For Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, [stevegentles@gmail.com](mailto:stevegentles@gmail.com)

Duku, Eric, Offord Centre For Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, [duku@mcmaster.ca](mailto:duku@mcmaster.ca)

Kerns, Connor M., Department of Psychology, University of British Columbia, [cmkerns@psych.ubc.ca](mailto:cmkerns@psych.ubc.ca)

McVey, Alana J., Department of Psychology, University of British Columbia, [amcvey@psych.ubc.ca](mailto:amcvey@psych.ubc.ca)

Hunsche, Michelle C., Department of Psychology, University of British Columbia, [michelle.hunsche@psych.ubc.ca](mailto:michelle.hunsche@psych.ubc.ca)

Ng-Cordell, Elise C., Department of Psychology, University of British Columbia, [elise.ngcordell@psych.ubc.ca](mailto:elise.ngcordell@psych.ubc.ca)

Bednar, E. Dimitra, Michael G. DeGroote School of Medicine, McMaster University, [dimitra.bednar@medportal.ca](mailto:dimitra.bednar@medportal.ca)

Laura Banfield, Health Sciences Library, McMaster University, [banfie@mcmaster.ca](mailto:banfie@mcmaster.ca)

Szatmari, Peter, Department of Psychiatry, Hospital for Sick Children, University of Toronto, Centre for Addiction and Mental Health, Toronto. [Peter.szatmari@utoronto.ca](mailto:Peter.szatmari@utoronto.ca)

1  
2  
3 Geogiades, Stelios, Offord Centre For Child Studies, Department of Psychiatry and  
4  
5 Behavioural Neurosciences, McMaster University, [georgis@mcmaster.ca](mailto:georgis@mcmaster.ca)  
6  
7  
8  
9

10  
11 Corresponding author:  
12

13  
14 Gentles, Stephen J., Offord Centre For Child Studies, McMaster University, Department of  
15  
16 Psychiatry and Behavioural Neurosciences, 175 Longwood Road South, Hamilton, Ontario, L8P  
17  
18 0A1, Canada, [stevegentles@gmail.com](mailto:stevegentles@gmail.com)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction.** Longitudinal trajectory methods, featuring outcome assessments at three or more timepoints, are increasingly being used as appropriate approaches to understand developmental pathways of people on the autism spectrum across the lifespan. Understanding the scope of this rapidly expanding body of research can help inform future trajectory studies and identify areas for potential meta-analysis as well as key evidence gaps. We present the protocol for a scoping review whose objective is to identify and summarize the scope of research that uses a longitudinal trajectory study design to examine development in children diagnosed with autism. Specifically, we will identify outcome domains and age intervals that have been well-characterized, areas where further research is needed, and the historical use of various longitudinal trajectory analytic approaches.

**Methods and analysis.** We outline the methods for the proposed scoping review according to the framework outlined by Arksey and O'Malley, with subsequent clarifications and enhancements by other authors. Using a search strategy developed by a medical librarian, we will search six databases for relevant publications. Titles and abstracts will be screened in duplicate, followed by full-text screening. Data extraction fields developed predominantly *a priori* from a set of guiding sub-questions will be used to chart relevant data. The findings will include quantitative aggregate summaries, narrative summaries, and appraisal of trajectory studies according to our methodological sub-questions. We will consult Autistic self-advocate and parent-caregiver stakeholders to facilitate interpretation of the findings.

**Ethics and dissemination.** Research ethics approval is not required for this scoping review. The results will be presented to researcher, care professional, policy-maker, and

1  
2  
3 stakeholder audiences at local and international conferences, other dissemination activities, and  
4  
5 published in a peer-reviewed journal.  
6  
7  
8  
9  
10

## 11 **Keywords**

12  
13  
14 Autism, longitudinal research, trajectory studies, scoping review, child development  
15

## 16 **Word count**

17  
18  
19 3636 words  
20  
21  
22  
23  
24

## 25 **Article Summary**

26  
27  
28 ‘Strengths and limitations of this study’  
29

- 30
- 31 • The scoping review whose protocol is presented will be the first to establish which outcome  
32 domains and age intervals have been characterized by longitudinal trajectory research  
33 examining development in children diagnosed with autism, and which warrant further study.  
34  
35
  - 36 • An innovative aspect of this scoping review will be its use of pre-specified sub-questions to  
37 guide development of the extraction (charting) form.  
38  
39
  - 40 • We will summarize information corresponding to methodological sub-questions that may  
41 provide a useful basis for future critical appraisal of trajectory studies in this area.  
42  
43
  - 44 • This review is limited in its scope because it excludes trajectory studies whose focus is on  
45 adulthood, and a separate review is therefore warranted to report on trajectories of outcome  
46 domains that may only be relevant at later life stages.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Background

Autism (autism spectrum disorder) is a neurodevelopmental condition recently estimated to affect 1 in 54 children [1], the prevalence of which is not likely to be substantively affected by geography, race, or socioeconomic factors [2]. The diagnosis is defined by variation in social communication and interaction, and restricted, repetitive patterns of behaviour, interests, or activities [3]. Autism is also increasingly being understood to be characterized by different strengths [4]. It has long been recognized that the characteristics used to define autism vary developmentally over the life-course, and that there is a need for rigorous longitudinal research to understand changes in relevant outcomes over time, identify prognostic factors, and understand what may improve developmental pathways of relevant outcome domains [5].

Trajectory methodology, defined here as featuring longitudinal analysis of assessments at three or more time points, has emerged as more appropriate for understanding development in autism compared to traditional cohort studies characterized by assessments at only two timepoints. In an early review of longitudinal research in autism that included studies with traditional cohort and cross-sectional designs, Selzer and colleagues [6] highlighted the key limitations of research featuring assessments at only two timepoints, noting it “makes it impossible to characterize the shape of the developmental function, the timing of changes, or the possibility that there are different subtypes of individuals on the autism spectrum characterized by different trajectories to the same outcome.” Recognizing these limitations, researchers in the field of autism have increasingly turned to trajectory methods, which feature assessments at three or more time points. Some large-scale longitudinal autism cohort research groups have published serial reports on the development of their child cohorts, increasing the number of assessments as they age over time (for example, [7, 8]). Such research has expanded our understanding of

1  
2  
3 autism in important ways, including by defining important variation in the developmental  
4 trajectories of children on the autism spectrum—variation that exists both between trajectory  
5 groups or clusters, and between children within those clusters (for example see, [9-11]).  
6  
7  
8  
9  
10 Consequently, other approaches, which simply report or graph average measures across  
11 individuals at each timepoint, have limited use for studying development in people on the autism  
12 spectrum, because they ignore and obscure the correlated nature of within-case data over time.  
13  
14  
15

16  
17 Given the expansion of published trajectory studies in autism, there is a need to understand  
18 its scope to provide a broad picture of aspects such as the variety of outcome domains (i.e.,  
19 measurable outcomes, which potentially vary over development) that have been studied over  
20 time, the age intervals over which outcome domains have been followed, and trends in the  
21 statistical analytic approaches that have been used. Two broad types of analytic approaches have  
22 been used to study autism trajectories: multi-level modeling (MLM), a variable-centred approach  
23 that estimates the average intercept and slope of the outcome domain of interest for pre-defined  
24 cohort groups (e.g., autistic, non-autistic); and growth mixture modeling (GMM), a person-  
25 centred approach that estimates distinct trajectories of latent groups formed on the basis of  
26 similar trajectories of individual participants within a cohort population.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 ***Previous reviews.*** The early reviews on longitudinal studies in autism (published 2004–  
42 2013) of which we are aware neglected to report a systematic search strategy, and have at least  
43 some focus on adults on the autism spectrum [5, 6, 12]. Three subsequent reviews of longitudinal  
44 autism research (published 2014 onwards), which did report a systematic search strategy,  
45 included studies following up to adulthood. Magiati and colleagues [13] included 25 studies and  
46 summarized findings from multiple outcome domains including cognitive ability, language,  
47 adaptive functioning, autism severity, and social functioning; a focus of this review was  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 childhood predictors of later outcomes, and a mix of studies using trajectory and traditional two-  
4  
5 timepoint cohort designs were included but not separated from each other in the review.  
6

7  
8 Bieleninik and colleagues [14] conducted a systematic review and meta-analysis that included 35  
9  
10 prospective cohort studies and 5 randomized controlled trials, and evaluated two outcome  
11  
12 domains: diagnostic stability, and autism symptom severity; trajectory studies were not  
13  
14 distinguished from two-timepoint follow-up studies. Howlin and Magiati [15] reviewed all adult  
15  
16 outcome-focused research (43 studies), of which five were trajectory studies described  
17  
18 individually in a separate section. A search for existing published (PubMed) or registered  
19  
20 (PROSPERO) protocols did not reveal other scoping reviews of trajectory studies in autism  
21  
22 research.  
23  
24

25  
26  
27 Our planned scoping study will be the first we are aware of to review research that uses a  
28  
29 longitudinal trajectory study design to study change in outcome domains over time in children on  
30  
31 the autism spectrum (to age 18). Notably, it will exclude studies whose focus is on adulthood  
32  
33 (i.e., where at least half of age timepoints assessed are above 18 years), because the set of  
34  
35 outcome domains that are relevant after the transition to adulthood differs sufficiently from  
36  
37 childhood, in our view, to warrant a separate review. Namely, some domains relevant to early  
38  
39 development (e.g., language) are generally less relevant in adulthood, while numerous adult-  
40  
41 relevant domains are inapplicable to early childhood (e.g., employment status, romantic  
42  
43 relationships). The planned review will address the breadth of outcome domains relevant to  
44  
45 children on the autism spectrum including clinical (developmental, behavioral, functional),  
46  
47 educational (e.g., academic achievement), and social. We will, however, exclude studies of  
48  
49 trajectories of neuroanatomical or physiological development, which have been previously  
50  
51 reviewed [16, 17].  
52  
53  
54  
55  
56  
57  
58  
59  
60



## **Objectives**

The primary objective of this scoping review is to identify and summarize the scope of research that uses a longitudinal trajectory study design (with three or more timepoints) to study the progression of different outcome domains—including the shape, timing and sub-groups—in children on the autism spectrum (to age 18). A secondary objective is to summarize methodological trends in terms of analytic approaches used in trajectory studies of child development in autism research. Findings from this review will provide a useful understanding of 1) how and where trajectory research has already been used, and the areas where future trajectory research can produce needed knowledge about autism (gaps), 2) specific outcome domains or research questions for which sufficient data exist to conduct more focused quantitative systematic reviews or meta-analyses, and 3) the general utility and value of trajectory study methodology for providing actionable knowledge to support positive development of children on the autism spectrum.

## **Methods and Analysis**

The scoping review methodology was judged to be appropriate for this review topic given its breadth, objectives, and the lack of known recent reviews on similar topics [18]. We outline the methods here according to the scoping review framework put forth by Arksey and O'Malley [19], informed by subsequent clarifications and enhancements [20, 21], reporting relevant elements outlined in the corresponding PRISMA Extension for Scoping Reviews (PRISMA-ScR) [22].

### *Stage 1: identifying the research question*

The primary objective and corresponding research question for this review was informed by the experience of review group members with trajectory studies of children on the autism spectrum (e.g., [7, 23, 24]) and by an examination of existing reviews on the topic which identified three narrative reviews in children [6, 16, 17] and five additional reviews of trajectories to adulthood [5, 12-15]. In addition to helping confirm the appropriateness and need for our focus on children, the examination of existing reviews helped us understand the potential scope of the literature and, later, to iteratively exclude two research categories we felt represented distinct topics of interest warranting separate reviews: 1) studies of trajectories of neuroanatomical or physiological development, and 2) descriptive case studies or case series of individual trajectories. The two primary research questions for this review that we used to inform study identification and selection are as follows:

- How has research that employs a longitudinal trajectory study design (i.e., featuring three or more timepoints and an aggregative statistical analysis that accounts for the correlated nature of within-case data over time) been used to produce knowledge about the change—including shape, timing and sub-groups—in child developmental, behavioral, functional, social, or outcome domains in children on the autism spectrum (to age 18)?
- What are some of the key methodological characteristics of this research?

The first question above identifies the key domains of our search strategy and screening criteria, namely the population (diagnosis and age), methodology, and outcome domains measured (i.e., non-anatomical). Under the umbrella of the primary research questions, lead

investigators on this review (SG, ED, SJG) also developed a set of sub-questions (Table 1) that were used to plan the data extraction and reporting of results, described below.

Table 1. Sub-questions to guide data extraction

<i>Questions about scope of the research</i>
1. What outcome domains have been studied in trajectory studies?
2. What outcome measures have been used to follow the different outcome domains over time?
3. What ages have been characterized for each outcome domain?
4. For studies using person-centred (GMM) approaches, how many trajectory groups (or clusters) have been defined for different outcome domains followed in different trajectory studies?
5. What and where are the different autism cohort research groups that have reported trajectory study findings?
6. To what extent have each of the different autism cohort research groups contributed to the trajectory study literature, and what are the general characteristics of their research (narrative summary)?
7. To what extent have the proposed implications (utility) of trajectory study findings been reported clearly?
8. How much impact (in terms of citation metrics) have different sources or types of trajectory research had?

***Questions about methodological aspects of research***

1. What terms (text words) have been used to describe multi-level modeling (MLM) and growth mixture modeling (GMM) trajectory studies of child development in autism?
2. How has the historical prevalence of MLM- and GMM-type trajectory approaches for studying development of children on the autism spectrum evolved by year?
3. How do select study characteristics (e.g., sample size, comparison to non-autism groups) vary between MLM- and GMM-type studies?
4. How reliable is the ascertainment of autism diagnosis in trajectory studies?
5. To what extent was representative sampling used across trajectory studies?
6. What other methodological aspects of trajectory research in autism could be used as a basis for identifying sources of risk of bias or for quality reporting standards?

***Stage 2: identifying relevant studies***

Our search was informed by the domains of the primary research question described above, and developed with the help of a medical librarian (LB), starting with Medline (OVID) because the subject heading definitions of this database are well developed (Table 2).

Table 2. MEDLINE search strategy.

1	exp Autism Spectrum Disorder/
2	Child Development Disorders, Pervasive/

3	Asperger*.mp.
4	ASD.mp.
5	autis*.mp.
6	or/1-5
7	exp Child/
8	child*.mp.
9	Adolescent/
10	Infant/
11	Infant, Newborn/
12	infan*.mp.
13	newborn*.mp.
14	Child, Preschool/
15	Child Development/
16	adolescen*.mp.
17	Pediatrics/
18	youth.mp.
19	teen*.mp.
20	p?ediatric*.mp.

21	or/7-20
22	trajector*.mp.
23	Longitudinal Studies/
24	Follow-Up Studies/
25	Prospective Studies/
26	longitudinal*.mp.
27	follow-up stud*.mp.
28	prospective*.mp.
29	followup stud*.mp.
30	Cohort Studies/
31	(cohort* stud* or cohort analys?s).mp.
32	panel stud*.mp.
33	or/22-32
34	6 and 21 and 33

The MEDLINE search was translated into the five other databases to be searched: EMBASE, CINAHL, PSYCInfo, ERIC, Cochrane Database of Systematic Reviews. Search results will be imported into EndNote reference management software (Clarivate Analytics), where duplicates will be removed and citations managed in the subsequent screening stages. We will not search the grey literature or conference proceedings, because we are interested in

1  
2  
3 mapping successfully peer-reviewed published literature that is likely to influence the field. For  
4 similar reasons, we will exclude doctoral theses or dissertations retrieved by the searches.  
5

6  
7 Searches will not be restricted by language or year of publication. We will include articles  
8  
9 published from database inception to the year 2020, based on a search completed May 24 of  
10  
11 2021. The expected study completion date is December 2021.  
12  
13

### 14 15 ***Stage 3: study selection*** 16

17  
18 After removal of duplicates from our EndNote database, we will select articles for  
19  
20 inclusion in the review through a two-step screening process: title and abstract, and full-text  
21  
22 screening. In both steps, all records will be screened in duplicate (by two reviewers), and  
23  
24 disagreements will be resolved through consensus in regular meetings. Reviewer decisions will  
25  
26 be recorded in EndNote, with mutual consensus required before an include or exclude decision is  
27  
28 reached. For the first step, title and abstract screening, screening decisions will err on the side of  
29  
30 inclusivity (sensitivity), so that records for which insufficient information is available in the title  
31  
32 or abstract will be included, and passed on, to the second screening step. Based on preliminary  
33  
34 work, in this step we expect to partially filter records based on indicators of diagnosis (autism),  
35  
36 age, and methodology (trajectory design), and definitively exclude records based on their identity  
37  
38 as case studies or series, trajectories of neuroanatomy or physiology, or non-published status  
39  
40 (e.g., dissertations or theses).  
41  
42  
43  
44  
45

46  
47 In the second step, the full text of articles will be retrieved (in PDF) and read to confirm  
48  
49 eligibility. Based on preliminary work, one of the predominant decisions in this step will be to  
50  
51 determine if studies qualify as true trajectory study methodology both in terms of the data  
52  
53 collection criterion (three timepoints or more) and two analysis criteria (analysis accounts for the  
54  
55 correlated nature of within-case data over time; and analysis does not simply average measures  
56  
57  
58  
59  
60

1  
2  
3 across individuals at each timepoint yielding only cross-sectional estimates). Given the potential  
4 number and complexity of analytic techniques, a statistician will be involved as a second  
5 reviewer for full-text screening decisions involving analysis-related criteria where necessary.  
6  
7  
8  
9  
10 Reasons for exclusions at the full-text screening step will be recorded in EndNote. A PRISMA  
11  
12 flow-chart will be used to report the results of the searches and both screening steps.  
13  
14

#### 15 ***Stage 4: charting the data***

16  
17  
18 The fields that we will extract data on (Table 3) have been developed as much as possible,  
19 a priori, from the sub-questions listed in Table 1. These fields are captured in an initial extraction  
20 form designed in Word, with the input of lead investigators (SG, ED, SJG) and the extraction  
21 team, to streamline the extraction process (e.g., containing in-line instructions, and other needed  
22 reference information). This form was piloted by the four-person extraction team (SJG, MCH,  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The form was judged easy to use by all, there was little disagreement, and misunderstandings  
were discussed and corrected. We anticipate it will be possible to develop a relatively stable form  
for addressing the pre-specified sub-questions. Nevertheless, we expect some unanticipated but  
important extraction fields will become apparent in the course of reviewing the included  
literature, which may require the iterative adaptation of the extraction form. Consequently, we  
have included a field in the extraction form to record ideas or suggestions for adaptation or  
revision that may iteratively arise when reviewing a specific article.

Information regarding methodological quality of individual studies will be extracted to  
address two of our sub-questions. Some extraction fields pertaining to trajectory methodology  
will be developed iteratively as there are no existing methodological quality criteria that we are  
aware of for this study design, and it is not possible to anticipate all aspects of quality in advance



of reviewing this literature. Additionally, quality indicators already accepted in the field of epidemiological autism research will be extracted, namely those pertaining to research-level diagnostic ascertainment standards.

Given the inevitability that there will be multiple publications by the same study group on the same cohort as it is reported on over multiple age timepoints, it may be possible to find helpful information pertaining to a given study in other publications by the same cohort research group. In addition to keeping careful records of which publications are linked in this way (as an extraction and reporting field of interest), we will assign papers belonging to the same cohort group to the same extractor so they can be aware of, and cross-reference as needed, the shared context of linked papers while extracting.

While articles will be extracted individually, we will have regular extraction meetings to discuss challenging articles, ideas for revising the extraction form, and other issues. Additionally, extractors will be able to consult with each other regarding areas of uncertainty related to specific publications. Finally, completed extraction forms will be verified by the review coordinator (SJG) before transferring their data to the analysis database, maintained in Excel, which will allow for aggregative summary and cross-tabulation of the extracted data. Fields in the Excel form will be programmed with data validation settings to minimize errors in data entry.

Table 3. Information fields for extraction from each included publication

Category	Information extraction field
Article characteristics	<ul style="list-style-type: none"> <li>• Year of publication</li> <li>• Article impact</li> </ul>

	<ul style="list-style-type: none"> <li>• Country(ies) of origin of cohort</li> <li>• Purpose of trajectory study (narrative)</li> <li>• Applicability of findings (narrative)</li> <li>• Clarity of applicability of findings</li> </ul>
Cohort research group	<ul style="list-style-type: none"> <li>• Autism Cohort Research Group: Title</li> <li>• Autism Cohort Research Group: Lead author</li> </ul>
Sample	<ul style="list-style-type: none"> <li>• Sample setting (community-based, clinical, etc.)</li> <li>• Type of sampling of autism participants (non-representative, representative)</li> <li>• Sample size, overall</li> <li>• Sample size, autism only</li> </ul>
Diagnostic ascertainment	<ul style="list-style-type: none"> <li>• Autism diagnosis methods reported?</li> <li>• Use of Autism Diagnostic Observation Schedule</li> <li>• Use of Autism Diagnostic Interview-Revised</li> <li>• Clinical judgment used</li> </ul>
Analysis	<ul style="list-style-type: none"> <li>• Prospective</li> <li>• MLM-type</li> <li>• MLM terms used</li> <li>• GMM-type</li> </ul>

	<ul style="list-style-type: none"> <li>• GMM terms used</li> <li>• Clarity of ages of assessment</li> </ul>
Outcome domain (repeated for each domain)	<ul style="list-style-type: none"> <li>• Outcome domain name</li> <li>• Measure used</li> <li>• Age interval start</li> <li>• Age interval end</li> <li>• Number of timepoints assessed</li> <li>• Ages of timepoints assessed</li> <li>• Rationale for ages assessed (narrative)</li> <li>• Clinical schedule used</li> <li>• Number of trajectory groups (clusters) defined</li> </ul>

### ***Stage 5: collating, summarising and reporting the results***

Along with presenting standard publication retrieval in a PRISMA flow chart, we plan to report on the number of unique studies that were captured by each successive database, from MEDLINE, to Embase, PsycINFO, CINAHL, ERIC, and Cochrane Reviews.

We expect a high number of included studies (>60), which may affect the level of aggregation we employ to summarize data presentations. We plan to present a summary table displaying key characteristics of the extracted literature, organized hierarchically by country, major cohort research group (where applicable), and individual publication (as hierarchically

1  
2  
3 indented rows); and include citations for each of the characteristics presented in columns—  
4  
5 including sample sizes, outcome domains followed, age interval followed, number of time  
6  
7 points, analytic approach, and citation impact. We also plan to use graphs to visually represent  
8  
9 data on historical trends in the use of MLM versus GMM analytic approaches over time, and on  
10  
11 the density of age timepoint assessments for each outcome domain. In addition, we will present  
12  
13 data that may provide a useful basis for future critical appraisal of trajectory studies according to  
14  
15 our methodological sub-questions regarding autism diagnosis ascertainment, and trajectory  
16  
17 review method reporting criteria. A table will display a proposed set of text words that can be  
18  
19 used to search for each type of trajectory analysis approach (MLM and GMM) in future.  
20  
21  
22  
23

24 A section of the review will provide narrative summaries to address the sub-question  
25  
26 regarding the impact and extent to which the major autism cohort research groups have  
27  
28 contributed to the trajectory study literature including general characteristics of their research.  
29  
30 Narrative will also be used to provide interpretive commentary on other sub-question–related  
31  
32 aspects, including suitability of the outcome measures that have been used to follow the different  
33  
34 outcome domains over time (including their patient-centeredness, per stakeholder consultation  
35  
36 described below), the number of trajectory groups (clusters) that have been defined for different  
37  
38 outcome domains, the extent to which the implications (or utility) of trajectory study findings  
39  
40 have been reported clearly, and the merit of future research to target gaps in the ages or outcome  
41  
42 domains not previously assessed.  
43  
44  
45  
46  
47

### 48 ***Patient and Public Involvement***

49

50  
51 Corresponding to Stage 6 of the Arksey–O’Malley scoping review framework (*optional*  
52  
53 *consultation exercise*), we have engaged two stakeholders in this review—an adult Autistic self-  
54  
55 advocate and a parent of a child on the autism spectrum—to provide feedback at key points. For  
56  
57  
58  
59  
60

1  
2  
3 purposes of this protocol, they have provided early feedback on aspects of the planned extraction  
4 related to outcome domains. This feedback informed plans for interpreting the relevance and  
5 importance of different outcomes in the final report, but it did not alter our decision to extract  
6 and report on all outcomes assessed by the studies to be included in this review. We did not  
7 involve patient stakeholders in development of the research question, or design of this study.  
8 While they will not be involved in data collection or analysis, we will re-engage these  
9 individuals once the review is complete to provide interpretations of the findings from their  
10 perspectives as members of the stakeholder community. Their interpretations will be used to  
11 inform the discussion of findings. We will also involve these individuals in presentations of the  
12 results described in the next section, according to their interest.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **Ethics and Dissemination**

27  
28  
29 The research ethics boards at our institutions do not need to be engaged to provide ethics  
30 approval for consulting with stakeholders about this research project since it does not involve  
31 their providing study data. We will follow best practices for patient engagement in research.  
32  
33  
34  
35  
36

37 This review will represent a source of valuable knowledge and guidance to researchers  
38 who are currently engaged in, or planning to conduct, longitudinal research on child  
39 development in autistic samples. It will also be of interest to clinicians, policy makers, and other  
40 professionals responsible for care or services for children on the autism spectrum, allowing them  
41 to quickly identify the trajectory literature on clinically-relevant outcome domains. It will also be  
42 of interest to families of children on the autism spectrum, who are known for their desire for  
43 access to research findings, by providing an overview of the kind of research that is often  
44 conducted to find answers about “what to expect” during the development of children on the  
45 autism spectrum. Finally, it will be useful to other reviewers seeking to identify one or more  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 outcome domains for which there is sufficient published trajectory research data to conduct a  
4 systematic review or meta-analysis. To reach these audiences, we plan to disseminate findings at  
5 major international autism research conferences, local autism conferences attended by families,  
6 and to publish the completed review in open access format in a peer-reviewed autism research  
7 journal. Other dissemination activities include plans to develop a webinar for parent and  
8 professional audiences, and lay research summaries for publication on provincial and national  
9 autism organization web sites.

### 19 **Acknowledgments**

20  
21  
22 The authors would also like to thank Trudy Goold and Connie Putterman for providing  
23 feedback from a stakeholder perspective on aspects of the proposed data extraction.

### 27 **Author contributions**

28  
29  
30 SJG, SG, and ED led the design and conceptualization. EDB, LB, and SJG developed the  
31 search strategy. AJM, EN-C, MCH, CMK, and PS were involved in design and conceptualization  
32 of the extraction form. SJG drafted the protocol. SG, ED, AJM, EN-C, MCH, CMK, and PS  
33 provided feedback and helped revise drafts of this manuscript for important intellectual content  
34 and clarity.

### 41 **Funding**

42  
43  
44 This research received no specific grant from any funding agency in the public,  
45 commercial or not-for-profit sectors.

### 52 **Competing interests**

53  
54  
55 None declared.

## References

1. Maenner, M.J., K.A. Shaw, J. Baio, EdS1, A. Washington, *et al.* Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. *MMWR Surveillance summaries : Morbidity and mortality weekly report Surveillance summaries / CDC*, 2020; 69(4): 1-12.  
<https://doi.org/10.15585/mmwr.ss6904a1>
2. Elsabbagh, M., G. Divan, Y.-J. Koh, Y.S. Kim, S. Kauchali, *et al.* Global prevalence of autism and other pervasive developmental disorders. *Autism Research*, 2012; 5(3): 160-179.  
<https://doi.org/10.1002/aur.239>
3. Association, A.P. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013: American Psychiatric Association. 1-36.
4. Mahdi, S. An International Clinical Study of Ability and Disability in Autism Spectrum Disorder Using the WHO-ICF Framework. *Journal of Autism and Developmental Disorders*, 2018; 48(6): 2148-2163. <https://doi.org/10.1007/s10803-018-3482-4>
5. Howlin, P. and P. Moss. Adults with autism spectrum disorders. *Canadian journal of psychiatry Revue canadienne de psychiatrie*, 2012; 57(5): 275-283.  
<https://doi.org/10.1177/070674371205700502>
6. Seltzer, M.M., P. Shattuck, L. Abbeduto, and J.S. Greenberg. Trajectory of development in adolescents and adults with autism. *Ment Retard Dev Disabil Res Rev*, 2004; 10(4): 234-47.  
<https://doi.org/10.1002/mrdd.20038>

- 1  
2  
3 7. Szatmari, P., S. Georgiades, E. Duku, T.A. Bennett, S. Bryson, *et al.* Developmental  
4 trajectories of symptom severity and adaptive functioning in an inception cohort of preschool  
5 children with autism spectrum disorder. *JAMA Psychiatry*, 2015; 72(3): 276-83.  
6  
7  
8  
9  
10 <https://doi.org/https://dx.doi.org/10.1001/jamapsychiatry.2014.2463>  
11  
12  
13 8. Gotham, K., A. Pickles, and C. Lord. Trajectories of autism severity in children using  
14 standardized ADOS scores. *Pediatrics*, 2012; 130(5): e1278-e1284.  
15  
16  
17 <https://doi.org/http://dx.doi.org/10.1542/peds.2011-3668>  
18  
19  
20 9. Georgiades, S., S.L. Bishop, and T. Frazier. Editorial Perspective: Longitudinal research  
21 in autism - introducing the concept of 'chronogeneity'. *Journal of Child Psychology and*  
22  
23  
24  
25 *Psychiatry*, 2017; 58(5): 634-636. <https://doi.org/10.1111/jcpp.12690>  
26  
27  
28 10. Charman, T. Mapping Early Symptom Trajectories in Autism Spectrum Disorder:  
29 Lessons and Challenges for Clinical Practice and Science. *Journal of the American Academy of*  
30  
31  
32  
33  
34 *Child and Adolescent Psychiatry*, 2018; 57(11): 820-821.  
35  
36 <https://doi.org/10.1016/j.jaac.2018.06.021>  
37  
38 11. Kim, S.H., V.H. Bal, N. Benrey, Y.B. Choi, W. Guthrie, *et al.* Variability in Autism  
39 Symptom Trajectories Using Repeated Observations From 14 to 36 Months of Age. *J Am Acad*  
40  
41  
42  
43  
44 *Child Adolesc Psychiatry*, 2018; 57(11): 837-848 e2. <https://doi.org/10.1016/j.jaac.2018.05.026>  
45  
46 12. Henninger, N.A. and J.L. Taylor. Outcomes in adults with autism spectrum disorders: a  
47 historical perspective. *Autism*, 2013; 17(1): 103-116. <https://doi.org/10.1177/1362361312441266>  
48  
49  
50 13. Magiati, I., X.W. Tay, and P. Howlin. Cognitive, language, social and behavioural  
51 outcomes in adults with autism spectrum disorders: A systematic review of longitudinal follow-  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 14. Bieleninik, L., M.B. Posserud, M. Geretsegger, G. Thompson, C. Elefant, and C. Gold.  
4 Tracing the temporal stability of autism spectrum diagnosis and severity as measured by the  
5 Autism Diagnostic Observation Schedule: A systematic review and meta-analysis. *PLoS One*,  
6 2017; 12(9): e0183160. <https://doi.org/10.1371/journal.pone.0183160>  
7  
8  
9  
10  
11  
12  
13 15. Howlin, P. and I. Magiati. Autism spectrum disorder: outcomes in adulthood. *Current*  
14 *Opinion in Psychiatry*, 2017; 30(2): 69-76. <https://doi.org/10.1097/YCO.0000000000000308>  
15  
16  
17  
18 16. Baribeau, D.A. and E. Anagnostou. A comparison of neuroimaging findings in childhood  
19 onset schizophrenia and autism spectrum disorder: a review of the literature. *Front Psychiatry*,  
20 2013; 4: 175. <https://doi.org/10.3389/fpsyt.2013.00175>  
21  
22  
23  
24  
25 17. Lainhart, J.E. Brain imaging research in autism spectrum disorders: in search of  
26 neuropathology and health across the lifespan. *Curr Opin Psychiatry*, 2015; 28(2): 76-82.  
27  
28 <https://doi.org/10.1097/yco.0000000000000130>  
29  
30  
31  
32  
33 18. Pollock, D., E.L. Davies, M.D.J. Peters, A.C. Tricco, L. Alexander, *et al.* Undertaking a  
34 scoping review: A practical guide for nursing and midwifery students, clinicians, researchers,  
35 and academics. *Journal of Advanced Nursing*, 2021; 77(4): 2102-2113.  
36  
37 <https://doi.org/10.1111/jan.14743>  
38  
39  
40  
41  
42 19. Arksey, H. and L. O'Malley. Scoping studies: towards a methodological framework.  
43 *International Journal of Social Research Methodology*, 2005; 8(1): 19-32.  
44  
45  
46  
47 20. Levac, D., H. Colquhoun, and K.K. O'Brien. Scoping studies: advancing the  
48 methodology. *Implementation science : IS*, 2010; 5(1): 69. [https://doi.org/10.1186/1748-5908-5-](https://doi.org/10.1186/1748-5908-5-69)  
49  
50  
51  
52 [69](https://doi.org/10.1186/1748-5908-5-69)  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
21. O'Brien, K.K., H. Colquhoun, D. Levac, L. Baxter, A.C. Tricco, *et al.* Advancing scoping study methodology: a web-based survey and consultation of perceptions on terminology, definition and methodological steps. 2016; 16(1): 1-12. <https://doi.org/10.1186/s12913-016-1579-z>
22. Tricco, A.C., E. Lillie, W. Zarin, K.K. O'Brien, H. Colquhoun, *et al.* PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Annals of Internal Medicine*, 2018; 169(7): 467-19. <https://doi.org/10.7326/M18-0850>
23. Szatmari, P., S. Bryson, E. Duku, L. Vaccarella, L. Zwaigenbaum, *et al.* Similar developmental trajectories in autism and Asperger syndrome: from early childhood to adolescence. *Journal of Child Psychology & Psychiatry & Allied Disciplines*, 2009; 50(12): 1459-67. <https://doi.org/https://dx.doi.org/10.1111/j.1469-7610.2009.02123.x>
24. Di Rezze, B., E. Duku, P. Szatmari, J. Volden, S. Georgiades, *et al.* Examining Trajectories of Daily Living Skills over the Preschool Years for Children with Autism Spectrum Disorder. *Journal of Autism and Developmental Disorders*, 2019: 1-10. <https://doi.org/10.1007/s10803-019-04150-6>

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
<b>Title</b>			
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	na
<b>Registration</b>			
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	na
<b>Authors</b>			
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	2
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the	21

guarantor of the review

## Amendments

[#4](#) If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

na

## Support

Sources [#5a](#) Indicate sources of financial or other support for the review 21

Sponsor [#5b](#) Provide name for the review funder and / or sponsor Na

Role of sponsor or funder [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol Na

## Introduction

Rationale [#6](#) Describe the rationale for the review in the context of what is already known 5-7

Objectives [#7](#) Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) 8-9

## Methods

Eligibility criteria [#8](#) Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 11-14

Information sources [#9](#) Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 13

Search strategy [#10](#) Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 11-13

Study records - data management [#11a](#) Describe the mechanism(s) that will be used to manage records and data throughout the review 13-14

Study records - [#11b](#) State the process that will be used for selecting studies (such as 14-15

1	selection process		two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	
2				
3				
4	Study records -	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as	15-16
5	data collection		piloting forms, done independently, in duplicate), any processes	
6	process		for obtaining and confirming data from investigators	
7				
8				
9	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as	16-17
10			PICO items, funding sources), any pre-planned data assumptions	
11			and simplifications	
12				
13				
14	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought,	16-17
15	prioritization		including prioritization of main and additional outcomes, with	
16			rationale	
17				
18				
19				
20	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of	15-16
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will be	
23			used in data synthesis	
24				
25				
26				
27	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be quantitatively	18-19
28			synthesised	
29				
30	Data synthesis	<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe planned	18-19
31			summary measures, methods of handling data and methods of	
32			combining data from studies, including any planned exploration	
33			of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	
34				
35				
36				
37	Data synthesis	<a href="#">#15c</a>	Describe any proposed additional analyses (such as sensitivity or	Na
38			subgroup analyses, meta-regression)	
39				
40				
41	Data synthesis	<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the type of	18-19
42			summary planned	
43				
44				
45	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such as	Na
46			publication bias across studies, selective reporting within studies)	
47				
48				
49	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be	na
50	cumulative		assessed (such as GRADE)	
51	evidence			
52				
53				

None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)